ArticleAnnals of clinical microbiology and antimicrobials2006
Identification of multi-drug resistant Pseudomonas aeruginosa clinical isolates that are highly disruptive to the intestinal epithelial barrier.
Article in Annals of clinical microbiology and antimicrobials, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- High frequency body site translocation of nosocomial Pseudomonas aeruginosa.Nature communications · 2025Article
- Subtractive Proteomic Approaches to Identify Drug Targets: An Analysis on Hypothetical Proteins of Multidrug-ResistantACS omega · 2025Article
- Dual-species proteomics and targeted intervention of animal-pathogen interactions.Journal of advanced research · 2025Article
- Article
- The relationship between ferroptosis and respiratory infectious diseases: a novel landscape for therapeutic approach.Frontiers in immunology · 2025Review
- A specific innate immune response silences the virulence of Pseudomonas aeruginosa in a latent infection model in the Drosophila melanogaster host.PLoS pathogens · 2024Article
- Tackling recalcitrant Pseudomonas aeruginosa infections in critical illness via anti-virulence monotherapy.Nature communications · 2022Article
- Bacteria-Derived Protein Aggregates Contribute to the Disruption of Host Proteostasis.International journal of molecular sciences · 2022Article
- P. aeruginosa augments irradiation injury via 15-lipoxygenase-catalyzed generation of 15-HpETE-PE and induction of theft-ferroptosis.JCI insight · 2022Article
- Adsorption of extracellular proteases and pyocyanin produced byCurrent research in microbial sciences · 2022Article
- Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules · 2021Review
- Antimicrobials as Single and Combination Therapy for Colistin-ResistantAntibiotics (Basel, Switzerland) · 2020Article
- Virulence Characteristics and an Action Mode of Antibiotic Resistance in Multidrug-Resistant Pseudomonas aeruginosa.Scientific reports · 2019Article
- Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.Nature communications · 2017Article
- Pseudomonas aeruginosa serA Gene Is Required for Bacterial Translocation through Caco-2 Cell Monolayers.PloS one · 2017Article
- Discovery of an inhibitor of the production of the Pseudomonas aeruginosa virulence factor pyocyanin in wild-type cells.Beilstein journal of organic chemistry · 2016Article
- The first 1000 cultured species of the human gastrointestinal microbiota.FEMS microbiology reviews · 2014Review
- Localization of DING proteins on PstS-containing outer-surface appendages of Pseudomonas aeruginosa.FEMS microbiology letters · 2014Article
- Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer.Frontiers in cellular and infection microbiology · 2014Review
- Design and synthesis of a biotinylated chemical probe for detecting the molecular targets of an inhibitor of the production of the Pseudomonas aeruginosa virulence factor pyocyanin.Molecules (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMulti-drug resistant Pseudomonas aeruginosa nosocomial infections are increasingly recognized worldwide. In this study, we focused on the virulence of multi-drug resistant clinical strains P. aeruginosa against the intestinal epithelial barrier, since P. aeruginosa can cause lethal sepsis from within the intestinal tract of critically ill and immuno-compromised patients via mechanisms involving disruption of epithelial barrier function.
methodsWe screened consecutively isolated multi-drug resistant P. aeruginosa clinical strains for their ability to disrupt the integrity of human cultured intestinal epithelial cells (Caco-2) and correlated these finding to related virulence phenotypes such as adhesiveness, motility, biofilm formation, and cytotoxicity.
resultsResults demonstrated that the majority of the multi-drug resistant P. aeruginosa clinical strains were attenuated in their ability to disrupt the barrier function of cultured intestinal epithelial cells. Three distinct genotypes were found that displayed an extreme epithelial barrier-disrupting phenotype. These strains were characterized and found to harbor the exoU gene and to display high swimming motility and adhesiveness.
conclusionThese data suggest that detailed phenotypic analysis of the behavior of multi-drug resistant P. aeruginosa against the intestinal epithelium has the potential to identify strains most likely to place patients at risk for lethal gut-derived sepsis. Surveillance of colonizing strains of P. aeruginosa in critically ill patients beyond antibiotic sensitivity is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.